ClinicalTrials.gg

Hypercholesterolemia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,177 studies for Hypercholesterolemia across more than 10 countries. 95 are recruiting or about to start. 821 of them are mainly about Hypercholesterolemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

ClinicalTrials.gov finds 1,489 studies for Hypercholesterolemia. How that becomes 1,175 here

This page counts the studies the registry files under Hypercholesterolemia, and those it files under no condition that list Hypercholesterolemiathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,489Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −204List Hypercholesterolemia as a condition, but the registry did not file them under itMost often written as “Familial Hypercholesterolemia” (79), “Homozygous Familial Hypercholesterolemia” (33), and “Hypercholesterolemia, Familial” (24). The registry filed 21 of them under no condition at all, and the others under other conditions only, most often Hyperlipoproteinemia Type II (129) and Homozygous Familial Hypercholesterolemia (52).
  3. −110Match it another way57 name it in the title, 14 in a keyword, and 39 by a synonym or other text the search reads.
  4. 1,175The count on this page42 of them list Hypercholesterolemia in their own words; the registry filed them under no condition.

Status

Completed
897
Status unknown
68
Terminated
62
Recruiting
55
Not yet recruiting
31
Active, not recruiting
30

Phase

Phase 3
295
Phase 4
152
Phase 2
145
Phase 1
111
Early Phase 1
8

Where

United States
379
Canada
124
Italy
81
Germany
81
Netherlands
81
United Kingdom
80

Who develops what

Add Hypercholesterolemia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 31 programs from 23 companies, 23 with this as their studies’ main aim; 8 with a live phase 3 study; 9 primary completions in the next 12 months. Compare AstraZeneca, Celltrion and Daiichi Sankyo here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
EzetimibeRecent, repeated
Evidence
  • NCT06450366 · Merck & Co., Inc · Phase 3 · comparator · “Ezetimibe” · registered Jun 2024
  • NCT05795517 · Haisco Pharmaceutical Group Co., Ltd. · Phase 2 · comparator · “Ezetimibe 10mg” · registered Mar 2023
  • NCT05763875 · Novartis · Phase 3 · comparator · “Ezetimibe” · registered Feb 2023
  • NCT05131997 · Yuhan Corporation · Phase 3 · comparator · “AD-221B” · registered Nov 2021
  • NCT04643093 · Orient Pharma Co., Ltd. · Phase 3 · comparator · “Ezetimibe” · registered Nov 2020
Organon & Co.59% of its industry studiesUS: off-patent, 14 generics marketed33 studies

14 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
inclisiranApproved: US 2021 · EU 2020☆ Track5 live phase-3 studies: NCT05030428, NCT05739383, NCT06597006Novartis
rosuvastatinApproved: US☆ Track3 live phase-3 studies: NCT07930507, NCT07619118, NCT07619131AstraZeneca
laroprovstat☆ Track3 live phase-3 studies: NCT07930507, NCT07619118, NCT07619131AstraZeneca
enlicitide decanoateApproved: US 2026☆ Track3 live phase-3 studies: NCT07821944, NCT06008756, NCT06492291Merck & Co., Inc
EzetimibeApproved: US☆ Track1 live phase-3 study: NCT07474649Daiichi Sankyo

The 5 in phase 3 with the nearest primary completion, of 31 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (9)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 27 Nov 2026 est.inclisiran · Novartis · Phase 4 main aimNCT06501443 LATAM LOWERS LDL-C — primary endpoint: Change in LDL-C from baseline to 330 days · 520 enrolled
  • 29 Dec 2026 est.alirocumab · Regeneron Pharmaceuticals · Phase 2 main aimNCT07477704 A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia — primary endpoint: Percent change in LDL-C · 438 enrolled
  • 28 Apr 2027 est.inclisiran, QCZ484 · Novartis · Phase 2 main aimNCT07610278 A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia — primary endpoint: Percent change from baseline of PCSK9 levels · 120 enrolled

6 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hypercholesterolemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here PCSK9 inhibitors 6 open · Statins 4 open · Angiotensin receptor blockers (ARBs) 1 open · Calcium channel blockers 5

Coming up

39studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger. 9 (16%) take children under 18. 1 (2%) are for women only and 1 (2%) for men only; 11 (20%) take healthy volunteers.

Recruiting studies that take each age, of 55
AgeWomenMen
109 (16%)8 (15%)
1844 (80%)44 (80%)
3047 (85%)47 (85%)
4050 (91%)50 (91%)
5050 (91%)50 (91%)
6549 (89%)49 (89%)
7539 (71%)39 (71%)
8530 (55%)30 (55%)

Across all 1,177 studies, recruiting or not: 42% stop at 75 or younger and 20% at 65; 9% take children; 2% are for women only and 3% for men only; 30% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hypercholesterolemia studies take

Of 125 phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 17 mo2–10 · 46 studies7 mo2–11 · 41 studies—
Phase 210 mo7–18 · 48 studies9 mo7–14 · 41 studies—
Phase 318 mo10–27 · 125 studies18 mo10–26 · 122 studies—
Phase 419 mo14–26 · 40 studies——
Interventional, no phase15 mo6–35 · 151 studies—16 mo6–36 · 133 studies
Observational33 mo22–59 · 51 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,177. Browse all 1,177 → or search them.